A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome

NCT06955143 | Recruiting

• 1 other identifier: SAHoWMU-CR2025-06-218
• Study Type: observational
• Target: 310
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are: The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.

Conditions

Acute Coronary Syndrome; Chronic Coronary Syndrome

Outcome Measures

Primary Outcomes (6)

• circulating fibroblast growth factors (FGFs) levels

  examining the circulating fibroblast growth factors levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospital

• circulating inflammatory cytokines levels

  examining the circulating inflammatory cytokines levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospital

• circulating chemokines levels

  examining the circulating chemokines levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospital

• circulating Cytochrome C level

  examining the circulating cytochrome c levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospita

• circulating mitochondrial DNA levels

  examining the circulating mitochondrial DNA levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospital

• circulating malondialdehyde levels

  examining the circulating malondialdehyde levels in the peripheral venous blood of the participants

  within 24 hours of admission to the hospital

Secondary Outcomes (7)

• the relationship between FGFs/inflammatory cytokines/chemokines and troponin I (TnI)

  within 24 hours of admission to the hospital

• the relationship between FGFs/inflammatory cytokines/chemokines and brain natriuretic peptide (BNP)

  within 24 hours of admission to the hospital

• the relationship between FGFs/inflammatory cytokines/chemokines and lactate dehydrogenase (LDH)

  within 24 hours of admission to the hospital

• the relationship between FGFs/inflammatory cytokines/chemokines and left ventricular ejection fraction (LVEF)

  within 24 hours of admission to the hospital

• the relationship between FGFs/inflammatory cytokines/chemokines and mitochondrial DNA (mitoDNA)

  within 24 hours of admission to the hospital

Study Arms (3)

ACS

those with a condition of Acute Coronary Syndrome

Control

patients without coronary artery disease, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy

CCS

those with a condition of Chronic Coronary Syndrome

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who presented to Lishui Central Hospital (Fifth Affiliated Hospital of Wenzhou Medical University) due to cardiac discomfort or other related symptoms were consecutively enrolled in the present study.

You may qualify if:

• For ACS group STEMI
• cTn\>99th ULN or CK-MB\>99th ULN
• ST-segment elevation with a convex upward morphology
• in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
• NSTEMI
• cTn\>99th ULN or CK-MB\>99th ULN
• accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.
• cTn normal
• ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves
• evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group
• Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD
• Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group
• Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy

You may not qualify if:

• Lactating or pregnant women
• Patients with malignant neoplasms
• Severe hepatic/renal dysfunction
• Severe hematological disorders
• Autoimmune diseases

Sponsors & Collaborators

• Second Affiliated Hospital of Wenzhou Medical University: lead
• The Central Hospital of Lishui City: collaborator

Study Sites (1)

Lishui Central Hospital

Lishui, Zhejiang, China

RECRUITING

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Central Study Contacts

Chao Niu, Doctor

CONTACT

86+18267806867; davidduoduo@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2025
• First Posted: May 2, 2025
• Study Start: March 11, 2025
• Primary Completion: August 1, 2025
• Study Completion: December 1, 2025
• Last Updated: July 25, 2025

Record last verified: 2025-07

Locations

CN (1)